Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns

ODAC will review currently available treatment options and negative treatment effects in subgroups as OSI seeks to expand Tarceva's indication to first-line maintenance and monotherapy in NSCLC.